Southwood, Taunton R <br/><br/>
Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Jan 2011 
 - 189-95 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1462-0332 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/keq308  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antibodies, Monoclonal--adverse effects<br/>Antirheumatic Agents--adverse effects<br/>Arthritis, Juvenile--drug therapy<br/>Biological Products--adverse effects<br/>Child<br/>Cohort Studies<br/>Etanercept<br/>Female<br/>Humans<br/>Immunoglobulin G--adverse effects<br/>Male<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Registries<br/>Time Factors<br/>Treatment Outcome<br/>Tumor Necrosis Factor Inhibitors<br/>Tumor Necrosis Factors--adverse effects<br/>United Kingdom<br/>Withholding Treatment